Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial.

TitleComparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial.
Publication TypeJournal Article
Year of Publication2015
AuthorsKhera, N, Majhail, NS, Brazauskas, R, Wang, Z, He, N, Aljurf, MD, Akpek, G, Atsuta, Y, Beattie, S, Bredeson, CN, Burns, LJ, Dalal, JD, Freytes, CO, Gupta, V, Inamoto, Y, Lazarus, HM, LeMaistre, CF, Steinberg, A, Szwajcer, D, Wingard, JR, Wirk, B, Wood, WA, Joffe, S, Hahn, TE, Loberiza, FR, Anasetti, C, Horowitz, MM, Lee, SJ
JournalBiol Blood Marrow Transplant
Volume21
Issue10
Pagination1815-22
Date Published2015 Oct
ISSN1523-6536
KeywordsAdolescent, Adult, Aged, Antilymphocyte Serum, Bone Marrow Transplantation, Child, Child, Preschool, Disease-Free Survival, Female, Graft vs Host Disease, Humans, Immunosuppressive Agents, Infant, Infant, Newborn, Inpatients, Male, Middle Aged, Myeloablative Agonists, Patient Selection, Peripheral Blood Stem Cell Transplantation, Proportional Hazards Models, Randomized Controlled Trials as Topic, Recurrence, Registries, Remission Induction, Research Subjects, Survival Analysis, T-Lymphocytes, Transplantation Conditioning, Treatment Outcome, Unrelated Donors, Young Adult
Abstract

Controversy surrounds the question of whether clinical trial participants have better outcomes than comparable patients who are not treated on a trial. We explored this question using a recent large, randomized, multicenter study comparing peripheral blood (PB) with bone marrow transplantation from unrelated donors, conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). We compared characteristics and outcomes of study participants (n = 494) and nonparticipants (n = 1384) who appeared eligible and received similar treatment without enrolling on the BMT CTN trial at participating centers during the study time period. Data were obtained from the Center for International Blood and Marrow Transplant Research. Outcomes were compared between the 2 groups using Cox proportional hazards regression models. No significant differences in age, sex, disease distribution, race/ethnicity, HLA matching, comorbidities, and interval from diagnosis to hematopoietic cell transplantation were seen between the participants and nonparticipants. Nonparticipants were more likely to have lower performance status, lower risk disease, and older donors, and to receive myeloablative conditioning and antithymocyte globulin. Nonparticipants were also more likely to receive PB grafts, the intervention tested in the trial (66% versus 50%, P

DOI10.1016/j.bbmt.2015.06.004
Alternate JournalBiol Blood Marrow Transplant
PubMed ID26071866
PubMed Central IDPMC4568172
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
UG1 HL069286 / HL / NHLBI NIH HHS / United States
UG1 HL069301 / HL / NHLBI NIH HHS / United States
U01 HL069246 / HL / NHLBI NIH HHS / United States
U24 CA076518 / CA / NCI NIH HHS / United States
U10 HL069286 / HL / NHLBI NIH HHS / United States
U10 HL069301 / HL / NHLBI NIH HHS / United States
HHSH250201200016C / / PHS HHS / United States
U10 HL109137 / HL / NHLBI NIH HHS / United States
U24-CA076518 / CA / NCI NIH HHS / United States
U10HL069294 / HL / NHLBI NIH HHS / United States
U10 HL069246 / HL / NHLBI NIH HHS / United States
U10 HL108987 / HL / NHLBI NIH HHS / United States